Thinking Out Loud (Blog)
September newsletter – Generic PANDA monium!
Generic PANDAmonium I have been hanging out with an old dog - eight year old Jack, during the COVID lockdown. If you are a dog during COVID-19, long walks, lots of snuggles on the couch during Zoom meetings, what's not to like? Hence the theme of my latest talk that...
read more
Time for T? Or, Are T-Cell-Driven Vaccines the Answer to COVID-19?
Time for T? Or Plan B for Operation Warp Speed? Six months ago, we asked if vaccine makers were rushing to “check the box” rather than spending time designing an effective vaccine (here is another link showing 'how to"). And have you noticed that all of the five top...
read more
Six months in, are we any closer to a vaccine?
Are we "Checking the Box" or Making Vaccines that work? We need a COVID-19 vaccine! From China to the US to Europe and even Africa, scientists are working tirelessly, if not at "warp speed", to develop and test more than one COVID-19 vaccine. May global scientific...
read more
Spy Vs Spy and … Making Better B-cell Derived Antibodies for COVID-19
Pepcid: From Poor Man's Cure to $20M COVID-19 Trial Remember Hydrocychloroquine? The drug that doesn't work for COVID-19? Well, here's some good news for you. A crazy rock climber/mountain rescue nut named Michael Callahan and a brilliant group of 3D modelers working...
read more
Press Release: PharmaJet partners with Immunomic Therapeutics and EpiVax to develop and deliver COVID-19 Vaccine
Originally published via PR Newswire GOLDEN, Colo., April 14, 2020 /PRNewswire/ -- PharmaJet®, the maker of innovative, needle-free injection technology, today announced that its Tropis® Needle-free injection system will be used to deliver a COVID-19 vaccine being...
read more
Press Release: Immunomic Therapeutics Forms Collaboration with EpiVax and PharmaJet to Develop Novel Vaccine Candidate Against COVID-19 Using its Investigational UNITE Platform
Read the original BusinessWire publication here. ROCKVILLE, MD, PROVIDENCE, RI, and GOLDEN, CO, April 09, 2020 -- Immunomic Therapeutics, Inc., a privately held clinical stage biotechnology company pioneering the study of nucleic acid immunotherapy platforms,...
read more